Primary Care CKD Registry

University of California, San Francisco746 enrolled

Overview

This study examines whether a safety-net primary care CKD registry directed at the entire primary care team can enhance the delivery of guideline concordant CKD care, including BP control, ACEi/ARB use and albuminuria quantification.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

746

Conditions

Hypertension Chronic Kidney Diseases

Interventions

CKD RegistryOTHER

Health Service intervention

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: All PCPs who worked in practice teams and provided longitudinal primary care to patients were eligible to participate in this study. Practice teams that consisted of several physicians (+/- trainees), one nurse, nurse practitioners, medical assistants and behaviorists, were randomized 1:1 to one of two arms with a random number generator: access to an electronic CKD registry or a usual care registry for 12 months. Exclusion Criteria: PCPs who solely provided specialty care, for example HIV services or urgent care, were excluded.

Outcomes

Primary Outcomes

Change in clinic systolic

Change in ambulatory systolic BP measured at ambulatory clinic visits in the health care system.

Time frame: 12 months

Secondary Outcomes

Change in proportion of patients with BP control

Change in the proportion of patients with BP control defined by BP \<140/\<90 mmHg at an ambulatory clinic visit.

Time frame: 12 months

Change in proportion fo patients with urine albuminuria quantification

Change in proportion of patients whose albuminuria was quantified by a urine test among those had not received quantification at trial initiation.

Time frame: 12 months

Change in albuminuria severity

Change in albuminuria severity (mg urine albumin/g urine creatinine) among those patients with albuminuria quantified at trial initiation

Time frame: 12 months

Change in proportion of patients with ACEi/ARB prescription

Change in proportion of patients prescribed an ACEi/ARB in the clinical record or had a documented reason for no prescription (i.e., allergy, prior development of hyperkalemia, or acute kidney injury)

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.